For the quarter ended June 2025, Steris (STE) reported revenue of $1.39 billion, up 8.7% over the same period last year. EPS came in at $2.34, compared to $2.03 in the year-ago quarter.
The reported revenue represents a surprise of +2.36% over the Zacks Consensus Estimate of $1.36 billion. With the consensus EPS estimate being $2.32, the EPS surprise was +0.86%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Applied Sterilization Technologies (AST): $281.2 million versus the four-analyst average estimate of $266.71 million. The reported number represents a year-over-year change of +12.6%.
- Revenues- Life Sciences: $135.2 million compared to the $136.48 million average estimate based on four analysts. The reported number represents a change of +5.2% year over year.
- Revenues- Healthcare: $974.7 million versus the four-analyst average estimate of $955.77 million. The reported number represents a year-over-year change of +8.2%.
- Operating income / (loss)- Healthcare: $235.5 million versus $225.54 million estimated by two analysts on average.
- Operating income / (loss)- Corporate and Other: $-114 million versus $-75.85 million estimated by two analysts on average.
- Operating income / (loss)- Applied Sterilization Technologies (AST): $136.7 million versus the two-analyst average estimate of $118.02 million.
- Operating income / (loss)- Life Sciences: $58.7 million compared to the $56.87 million average estimate based on two analysts.
View all Key Company Metrics for Steris here>>>
Shares of Steris have returned -3.7% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
STERIS plc (STE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
